Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asia Pacific

Set Alert for Asia Pacific

Entry Reminder For Pharma Intelligence Awards Japan

The 4 February entry deadline is looming for the inaugural Informa Pharma Intelligence Awards Japan, which will be held in Tokyo on 12 May 2022 to recognize and reward the very best innovations and achievements in pharma and biotech, highlighting Japan's integral role in the global healthcare market.

Japan Commercial

Year Of IP: From The TRIPS Waiver Proposal To The Moderna-NIH Patent Tussle

Intellectual property became front page news in 2021 as the pandemic ignited a debate on the role of patents in accessing COVID-19 vaccines and therapeutics. 2022 will see a decision on the TRIPS waiver, a new USPTO director, and action on a pending march-in petition.

Intellectual Property Pink Sheet Perspectives

2021 Saw India Enable Accelerated Regulatory Pathways – Can It Become The Norm?

India saw a raft of vaccine and drug approvals in 2021, backed by pandemic-related accelerated regulatory processes, and outlined its intent to step up biopharma innovation in the country.  Pharma wants some of the regulatory flexibility to stay, though experts are seeking increased transparency in the overall approach.

Approvals Drug Approval Standards

J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies. 

Companies Deals

Global Pharma Guidance Tracker – December 2021

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Guidance Documents Regulation

Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments

Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.

Intellectual Property Legal Issues

Korea Policies To Shift To Non-COVID Areas In 2022?

The Pink Sheet takes a look back at major policy developments in South Korea in 2021 and ahead at what’s in store for the coming year.

South Korea Pink Sheet Perspectives

Oncology Dominates China's 43 New Approvals In 2021, Domestics Emerge To Lead Innovation

Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.

China Approvals

In Case You Missed It: RWE, US FDA Commissioner Hearings, 2021 Approval Trends, And More

Start the new year by catching up with these key stories posted by the Pink Sheet in late December.

Health Technology Assessment Real-World Evidence

Coronavirus Notebook: Vaccine Approvals In India Amid Wins And Losses For Drug Developers In China

India has issued emergency approvals for a number of new COVID-19 vaccines and extended eligible age groups for others, while developers of potential drug therapies in China have seen both gains and setbacks. 

Coronavirus COVID-19 Vaccines

Korea Expands Financial Support For Global Innovation Bid

While keeping its policy focus mainly on controlling the pandemic situation, South Korea is also increasing R&D grants to support the development of innovative drugs with global blockbuster potential through the launch of renewed and better funded Korea Drug Development Fund.

South Korea Policy

South Korea Deliberates Digital Healthcare Pathway

A recent policy forum discussed how South Korea should move forward to grab opportunities in digital healthcare and ensure global competitiveness in the COVID-19 pandemic era.

South Korea Digital Health
See All
UsernamePublicRestriction

Register